Analysis of Levodopa Content in Commercial Mucuna pruriens Products Using High-Performance Liquid Chromatography with Fluorescence Detection.
Level 5 - mechanism / opinion, no new human data
Laboratory bench study analyzing product chemistry without human subjects
PubMed 28922612 · doi:10.1089/acm.2017.0054
What was done
Researchers quantified levodopa content in 6 commercial Mucuna pruriens products using solvent extraction followed by reversed-phase high-performance liquid chromatography with fluorescence detection (HPLC-FD). They also evaluated manufacturer Certificates of Analysis (COAs) to assess quality specifications and verification practices.
What was found
Levodopa content ranged from 6% to 141% of individual label claims across the 6 tested products. None of the products fell within standard pharmacopeial limits of 90% to 110% of label claim. Estimated maximum daily doses varied widely from 14.4 to 720 mg/day. Manufacturer COAs were inconsistent in specification and verification standards.
Why it matters
Patients with Parkinson's disease using over-the-counter Mucuna pruriens supplements face unpredictable levodopa dosing ranging from ineffective to potentially toxic, which also undermines scientific studies relying on commercial formulations.
Limits
Only 6 commercial products were tested. The study evaluated product chemical content in vitro, without measuring batch-to-batch variability over time or direct clinical outcomes in patients.
Cited by
- contradicts The Mucuna pruriens bean contains 99% L-dopa.